SEC Form 4 · accession 0000899243-18-031625
Global Blood Therapeutics, Inc. · GBT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dawn Svoronos
Director
Period of report
Dec 19, 2018
Accepted (ET)
Dec 21, 2018 · 6:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001629137
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $38.68 | Dec 19, 2018 | A | 30,000 | A | — | Dec 18, 2028 | Common Stock | 30,000 | 30,000 | D |
Explanation of responses
- F1The shares vest and become exercisable in 36 equal monthly installments with the first installment on January 19, 2019, subject to the recipient's continued service on the Issuer's Board of Directors. This option is subject to accelerated vesting upon a change of control of the Issuer.